The increased understanding of the immunological behaviour of CD8+ T-cells has added a new perspective in the management advanced tumours and led to the development of newer drugs as checkpoint inhibitors, which augment the CD8+ T cells [88,89]. This evidence concerns the gene CD8A and neoplasm.